Lapatinib

From Anvita Health Wiki

Contents 1 Indications 2 Dosage 3 Monitor 4 Adverse-effects 5 Mechanism-of-action 6 More General Terms 7 Additional Terms 8 References

Indications

• adjunct treatment of breast cancer

• used in combination with capecitabine [1]

Dosage

• 1250 mg PO QD

Monitor

• liver function tests ( serum ALT, serum AST, serum bilirubin, serum alkaline phosphatase) baseline, then every 4-6 weeks & as clinically indicated [2]

Adverse-effects

• somewhat difficult to assess given the patient popluation & other treatments
• most common: diarrhea, dyspepsia, rash
• hepatoxicity [2]

Mechanism-of-action

• small-molecule tyrosine kinase inhibitor of HER1 & HER2
• antineoplastic activity in patients with HER2-positive metastatic breast cancer, including inflammatory breast cancer

More General Terms

• antineoplastic agent (chemotherapeutic agent)

Additional Terms

• chemotherapy for breast cancer

References

1. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. PMID: [1]
2. Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: [2] (subscription needed) [3]

lapatinib (Tykerb)